Cargando…
Multimodal targeting of glioma with functionalized nanoparticles
The most common and aggressive primitive intracranial tumor of the central nervous system is the glioma. The blood–brain barrier (BBB) has proven to be a significant obstacle to the effective treatment of glioma. To effectively treat glioma, different ways have been used to cross the BBB to deliver...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396820/ https://www.ncbi.nlm.nih.gov/pubmed/35999629 http://dx.doi.org/10.1186/s12935-022-02687-8 |
_version_ | 1784772003563044864 |
---|---|
author | Marei, Hany E. |
author_facet | Marei, Hany E. |
author_sort | Marei, Hany E. |
collection | PubMed |
description | The most common and aggressive primitive intracranial tumor of the central nervous system is the glioma. The blood–brain barrier (BBB) has proven to be a significant obstacle to the effective treatment of glioma. To effectively treat glioma, different ways have been used to cross the BBB to deliver drugs to the brain. Drug delivery through nanocarriers proves to be an effective and non-invasive technique for the treatment of glioma and has great potential in the treatment of glioma. In this review, we will provide an overview of nanocarrier-mediated drug delivery and related glioma therapy. Nanocarrier-mediated drug delivery techniques to cross the BBB (liposomes, micelles, inorganic systems, polymeric nanoparticles, nanogel system, and biomimetic nanoparticles) are explored. Finally, the use of nanotherapeutic approaches in the treatment of glioblastoma including chemotherapy, radiotherapy, photothermal therapy, gene therapy, glioma genome editing, immunotherapy, chimeric antigen receptor (CAR) T-cells, immune checkpoint modulators, immune photothermal therapy, vaccine-based immunotherapy, and combination therapy is summarized. Furthermore, this article offers various views on the clinical applicability of nanomedicine. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12935-022-02687-8. |
format | Online Article Text |
id | pubmed-9396820 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-93968202022-08-24 Multimodal targeting of glioma with functionalized nanoparticles Marei, Hany E. Cancer Cell Int Review The most common and aggressive primitive intracranial tumor of the central nervous system is the glioma. The blood–brain barrier (BBB) has proven to be a significant obstacle to the effective treatment of glioma. To effectively treat glioma, different ways have been used to cross the BBB to deliver drugs to the brain. Drug delivery through nanocarriers proves to be an effective and non-invasive technique for the treatment of glioma and has great potential in the treatment of glioma. In this review, we will provide an overview of nanocarrier-mediated drug delivery and related glioma therapy. Nanocarrier-mediated drug delivery techniques to cross the BBB (liposomes, micelles, inorganic systems, polymeric nanoparticles, nanogel system, and biomimetic nanoparticles) are explored. Finally, the use of nanotherapeutic approaches in the treatment of glioblastoma including chemotherapy, radiotherapy, photothermal therapy, gene therapy, glioma genome editing, immunotherapy, chimeric antigen receptor (CAR) T-cells, immune checkpoint modulators, immune photothermal therapy, vaccine-based immunotherapy, and combination therapy is summarized. Furthermore, this article offers various views on the clinical applicability of nanomedicine. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12935-022-02687-8. BioMed Central 2022-08-23 /pmc/articles/PMC9396820/ /pubmed/35999629 http://dx.doi.org/10.1186/s12935-022-02687-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Marei, Hany E. Multimodal targeting of glioma with functionalized nanoparticles |
title | Multimodal targeting of glioma with functionalized nanoparticles |
title_full | Multimodal targeting of glioma with functionalized nanoparticles |
title_fullStr | Multimodal targeting of glioma with functionalized nanoparticles |
title_full_unstemmed | Multimodal targeting of glioma with functionalized nanoparticles |
title_short | Multimodal targeting of glioma with functionalized nanoparticles |
title_sort | multimodal targeting of glioma with functionalized nanoparticles |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396820/ https://www.ncbi.nlm.nih.gov/pubmed/35999629 http://dx.doi.org/10.1186/s12935-022-02687-8 |
work_keys_str_mv | AT mareihanye multimodaltargetingofgliomawithfunctionalizednanoparticles |